Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,001)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04172532 | Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05304481 | Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma | recruiting | Phase 2 | 95 | Lukas Biomedical Inc.INDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05627635 | FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 20 | City of Hope Medical CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05672316 | Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy | active not recruiting | Phase 1 / Phase 2 | 28 | City of Hope Medical CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05727176 | Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement(FOENIX-CCA4) | recruiting | Phase 2 | 120 | Taiho Oncology, Inc.INDUSTRY | 13 | Sep 1, 2026 | clinicaltrials |
| NCT05945823 | Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | active not recruiting | Phase 2 | 53 | Taiho Oncology, Inc.INDUSTRY | 4 | Sep 1, 2026 | clinicaltrials |
| NCT06294548 | A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC | recruiting | Phase 1 / Phase 2 | 45 | University of Alabama at BirminghamOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06992258 | A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer(FRUITION) | recruiting | Phase 2 | 120 | Criterium, Inc.INDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07294664 | PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer | recruiting | Phase 2 | 78 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07797816 | Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer | recruiting | Phase 2 | 31 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT03505320 | A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer(ILUSTRO) | active not recruiting | Phase 2 | 143 | Astellas Pharma Global Development, Inc.INDUSTRY | 6 | Aug 31, 2026 | clinicaltrials |
| NCT03652428 | Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC) | active not recruiting | Phase 1 / Phase 2 | 24 | University of Maryland, BaltimoreOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07736612 | A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 80 | Zhejiang UniversityOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07795749 | Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B) | recruiting | Phase 2 | 55 | University of California, IrvineOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07796113 | Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC | recruiting | Phase 2 | 24 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT02867592 | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | active not recruiting | Phase 2 | 109 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04379596 | Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)(DG-03) | active not recruiting | Phase 2 | 452 | AstraZenecaINDUSTRY | 14 | Aug 28, 2026 | clinicaltrials |
| NCT04486378 | A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | active not recruiting | Phase 2 | 327 | BioNTech SEINDUSTRY | 7 | Aug 28, 2026 | clinicaltrials |
| NCT06529718 | Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients(SEVILLA) | recruiting | Phase 2 | 72 | UNICANCEROTHER | 2 | Aug 28, 2026 | clinicaltrials |
| NCT06596694 | Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02) | recruiting | Phase 1 / Phase 2 | 180 | Merck Sharp & Dohme LLCINDUSTRY | 15 | Aug 28, 2026 | clinicaltrials |
| NCT07070466 | Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA | recruiting | Phase 2 | 40 | Massachusetts General HospitalOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07632235 | A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma | not yet recruiting | Phase 1 / Phase 2 | 112 | Shanghai 6th People's HospitalOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07793253 | Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer | not yet recruiting | Phase 2 | 55 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07071961 | Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial] | recruiting | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07224022 | Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer(NACho) | not yet recruiting | Phase 2 | 24 | John Strickler, M.D.OTHER | 0 | Aug 27, 2026 | clinicaltrials |
| NCT07474727 | A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer | recruiting | Phase 2 | 180 | Multitude Therapeutics Inc.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07640295 | Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations | recruiting | Phase 1 / Phase 2 | 80 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07753824 | A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA) | not yet recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07789210 | A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mutant Colorectal Cancer With or Without Resectable Metastases(NEORAF) | recruiting | Phase 2 | 25 | Zhejiang UniversityOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07790510 | HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 180 | Haisco Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT05063565 | TheraSphere With Durvalumab and Tremelimumab for HCC(ROWAN) | active not recruiting | Phase 2 | 100 | Boston Scientific CorporationINDUSTRY | 5 | Aug 26, 2026 | clinicaltrials |
| NCT06187961 | HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma(CCGLC-011) | recruiting | Phase 2 | 36 | Tongji HospitalOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06313970 | First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients | active not recruiting | Phase 2 | 58 | Fudan UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06938282 | An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer | recruiting | Phase 2 | 60 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07551778 | Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 42 | BOE Technology Group Co., Ltd.INDUSTRY | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07700667 | SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 120 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07786766 | Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma | recruiting | Phase 2 | 154 | Haitao Zhao, MDOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07787273 | Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 84 | Hefei Cancer Hospital of the Chinese Academy of SciencesNETWORK | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07788664 | Local and Systemic Immune Modulation by Rilvegostomig (AZD2936) in the Treatment of Advanced Gastric Cancer (RILVE Project)(RILVE) | not yet recruiting | Phase 2 | 50 | Vall d'Hebron Institute of OncologyOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05789485 | A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers | recruiting | Phase 2 | 216 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06617858 | Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment | recruiting | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06923475 | Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma(NEODISCO) | recruiting | Phase 2 / Phase 3 | 150 | Amsterdam UMC, location VUmcOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07594626 | BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion | recruiting | Phase 1 / Phase 2 | 72 | Northwestern UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07689175 | Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma | recruiting | Phase 2 | 60 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07784374 | A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation | not yet recruiting | Phase 2 | 120 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT02008656 | Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management | active not recruiting | Phase 2 | 358 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03190941 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients | recruiting | Phase 1 / Phase 2 | 110 | National Cancer Institute (NCI)NIH | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05775159 | Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | active not recruiting | Phase 2 | 294 | AstraZenecaINDUSTRY | 9 | Aug 24, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Sep 1, 2026source: clinicaltrials